Clinical trial NCT04471779: Information About Alzheimer's Disease for Latinos in New York City
Official title: The IDEAL Study: Information About Alzheimer's Disease for Latinos in New York City
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Alzheimer Disease
Keywords: Latinos
New York (NY)
Genetics
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
First posted: 2020-07-15
Enrollment: 374
Sex: ALL
Minimum age (years): 40
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The investigators estimate that 2171 people will participate in the Baseline Survey, of whom 400 will be randomized and included in the follow-up study. Half of those in the follow-up study will be randomized to receive information about their risk of Alzheimer's disease based on Latino ethnicity, family history, and APOE genotype, and half will be randomized to receive information about their risk based on ethnicity and family history alone.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study will assess the psychosocial and behavioral impacts of receiving Alzheimer's disease genetic risk assessment incorporating APOE genotypes among Latinos in northern Manhattan. The investigators will conduct a longitudinal, community-based study with a mixed methods design. Participants will be randomized to learn about their lifetime risk of late-onset Alzheimer's disease (AD) based either on (a) Latino ethnicity and family history alone (genotype nondisclosure group), or (b) the same factors plus APOE genotype (genotype disclosure group). Responses will be evaluated at 6 weeks, 9 months, and 15 months after risk assessment. In the quantitative component of the study, the investigators will assess psychosocial outcomes, memory test performance, and health-related behaviors. In the qualitative component of the study, the investigators will investigate the lived experience of receiving personal AD risk information, using a stress and coping theoretical framework.

Detailed description: Apolipoprotein E (APOE) is the strongest genetic predictor of risk for late-onset Alzheimer's disease (AD). Given the high level of interest in genetic testing, the demand for predictive testing for APOE will surely increase. Improved understanding of the impacts of testing, sources of variability in response, and inclusion of diverse samples are critical for informing methods to promote safe and effective disclosure of AD genetic risk information.

As with other diseases, previous research on AD, a devastating and incurable illness, has found little significant or sustained distress in response to genetic susceptibility testing for APOE, even among persons who learn they are at elevated risk. These surprising findings, which run counter to the experience of many clinicians, may be related to limitations in the methods of previous studies. Most previous studies primarily enrolled well-educated Caucasians with a family history, who were strongly motivated to pursue genetic risk information. Further, most studies assessed impacts primarily through standardized measures of depression and anxiety, which may not capture the kinds of distress experienced or coping strategies that might blunt or mask distress. Qualitative research shows that receipt of genetic information can have important psychosocial effects not well captured through standardized measures. Also, in one study, people with a high-risk gene test for APOE performed worse on memory tests if they were informed about the results than if they were not informed, suggesting that other impact measures are needed.

Another important limitation of prior work is that it has lacked representation of ethnic minority groups. Latinos are the second largest U.S. ethnic group, comprising about 18% of the population, yet no previous study has investigated the impacts of receiving AD genetic risk information among Latinos. While AD incidence rates may vary among Latino subgroups, data from the Washington Heights-Inwood Columbia Aging Project (WHICAP), a study in northern Manhattan, indicate that they are about twice as high among Caribbean Hispanics (primarily Dominicans) as among persons of European ancestry.

In this study, the investigators will improve understanding of the impacts of receiving personal AD genetic risk information and the factors that influence adjustment to such information among Latinos who live in the same communities studied in WHICAP.

Eligibility criteria: Inclusion Criteria:

* self-identified as Latino or Hispanic
* age 40-64 years
* current residence in target neighborhoods: Washington Heights, Inwood, Hamilton Heights, Central Harlem, East Harlem, Morningside Heights, Manhattanville, or Striver's Row, New York

Exclusion Criteria:

* does not self-identify as Latino
* does not reside in target neighborhoods
* not in applicable age range
* has Alzheimer's disease
* previously tested for APOE
* has a family history consistent with autosomal dominant, early onset Alzheimer's disease
* has a positive screen for suicidality in Baseline Survey (any response other than "not at all" to PHQ-9 item, "thoughts that you would be better off dead or of hurting yourself in some way")

Primary outcomes:
measure: Impact of Genetic Testing in AD (IGT-AD)
timeFrame: 6 weeks after risk evaluation
measure: Impact of Genetic Testing in AD (IGT-AD)
timeFrame: 9 months after risk evaluation
measure: Impact of Genetic Testing in AD (IGT-AD)
timeFrame: 15 months after risk evaluation
measure: Impact of Event Scale-Revised
timeFrame: 6 weeks after risk evaluation
measure: Impact of Event Scale-Revised
timeFrame: 9 months after risk evaluation
measure: Impact of Event Scale-Revised
timeFrame: 15 months after risk evaluation
measure: Change in Score on the Brief Test of Adult Cognition by Telephone (BTACT)
timeFrame: Baseline and 6 weeks after risk evaluation
measure: Change in Score on the Brief Test of Adult Cognition by Telephone (BTACT)
timeFrame: Baseline and 9 months after risk evaluation
measure: Change in Score on the Brief Test of Adult Cognition by Telephone (BTACT)
timeFrame: Baseline and 15 months after risk evaluation
measure: Change in Score on the Metamemory in Adulthood Questionnaire-Revised
timeFrame: Baseline and 6 weeks after risk evaluation
measure: Change in Score on the Metamemory in Adulthood Questionnaire-Revised
timeFrame: Baseline and 9 months after risk evaluation
measure: Change in Score on the Metamemory in Adulthood Questionnaire-Revised
timeFrame: Baseline and 15 months after risk evaluation
Secondary outcomes:
measure: Change in Score on Patient Health Questionnaire-9 (PHQ-9)
timeFrame: Baseline and 6 weeks after risk evaluation
measure: Change in Score on Patient Health Questionnaire-9 (PHQ-9)
timeFrame: Baseline and 9 months after risk evaluation
measure: Change in Score on Patient Health Questionnaire-9 (PHQ-9)
timeFrame: Baseline and 15 months after risk evaluation
measure: Change in Score on the General Anxiety Disorder-7 (GAD-7)
timeFrame: Baseline and 6 weeks after risk evaluation
measure: Change in Score on the General Anxiety Disorder-7 (GAD-7)
timeFrame: Baseline and 9 months after risk evaluation
measure: Change in Score on the General Anxiety Disorder-7 (GAD-7)
timeFrame: Baseline and 15 months after risk evaluation
measure: Change in Perceived Threat of AD
timeFrame: Baseline and 6 weeks after risk evaluation
measure: Change in Perceived Threat of AD
timeFrame: Baseline and 9 months after risk evaluation
measure: Change in Perceived Threat of AD
timeFrame: Baseline and 15 months after risk evaluation
measure: Health-related behavior changes
timeFrame: 6 weeks after risk evaluation
measure: Health-related behavior changes
timeFrame: 9 months after risk evaluation
measure: Health-related behavior changes
timeFrame: 15 months after risk evaluation
measure: Recall/understanding of results
timeFrame: 6 weeks after risk evaluation
measure: Recall/understanding of results
timeFrame: 9 months after risk evaluation
measure: Recall/understanding of results
timeFrame: 15 months after risk evaluation
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Irving Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Ruth Ottman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Molinuevo JL, Pintor L, Peri JM, Lleo A, Oliva R, Marcos T, Blesa R. Emotional reactions to predictive testing in Alzheimer's disease and other inherited dementias. Am J Alzheimers Dis Other Demen. 2005 Jul-Aug;20(4):233-8. doi: 10.1177/153331750502000408.
citation: Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med. 2008 Jan;10(1):19-32. doi: 10.1097/GIM.0b013e31815f524f.
citation: Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA; REVEAL Study Group. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009 Jul 16;361(3):245-54. doi: 10.1056/NEJMoa0809578.
citation: Bemelmans SA, Tromp K, Bunnik EM, Milne RJ, Badger S, Brayne C, Schermer MH, Richard E. Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. Alzheimers Res Ther. 2016 Nov 10;8(1):46. doi: 10.1186/s13195-016-0212-z.
citation: Vos J, van Asperen CJ, Oosterwijk JC, Menko FH, Collee MJ, Gomez Garcia E, Tibben A. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters. Psychooncology. 2013 Apr;22(4):902-10. doi: 10.1002/pon.3081. Epub 2012 Jun 27.
citation: Gooding HC, Linnenbringer EL, Burack J, Roberts JS, Green RC, Biesecker BB. Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns. 2006 Dec;64(1-3):259-67. doi: 10.1016/j.pec.2006.03.002. Epub 2006 Jul 21.
citation: Zallen DT. "Well, good luck with that": reactions to learning of increased genetic risk for Alzheimer disease. Genet Med. 2018 Nov;20(11):1462-1467. doi: 10.1038/gim.2018.13. Epub 2018 Mar 8.
citation: Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry. 2014 Feb;171(2):201-8. doi: 10.1176/appi.ajp.2013.12121590.
citation: Aviles-Santa ML, Heintzman J, Lindberg NM, Guerrero-Preston R, Ramos K, Abraido-Lanza AL, Bull J, Falcon A, McBurnie MA, Moy E, Papanicolaou G, Pina IL, Popovic J, Suglia SF, Vazquez MA. Personalized medicine and Hispanic health: improving health outcomes and reducing health disparities - a National Heart, Lung, and Blood Institute workshop report. BMC Proc. 2017 Oct 3;11(Suppl 11):11. doi: 10.1186/s12919-017-0079-4. eCollection 2017.
citation: Mehta KM, Yeo GW. Systematic review of dementia prevalence and incidence in United States race/ethnic populations. Alzheimers Dement. 2017 Jan;13(1):72-83. doi: 10.1016/j.jalz.2016.06.2360. Epub 2016 Sep 4.
citation: Tang MX, Maestre G, Tsai WY, Liu XH, Feng L, Chung WY, Chun M, Schofield P, Stern Y, Tycko B, Mayeux R. Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet. 1996 Mar;58(3):574-84.
citation: Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, Andrews H, Feng L, Tycko B, Mayeux R. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998 Mar 11;279(10):751-5. doi: 10.1001/jama.279.10.751.
citation: Gurland BJ, Wilder DE, Lantigua R, Stern Y, Chen J, Killeffer EH, Mayeux R. Rates of dementia in three ethnoracial groups. Int J Geriatr Psychiatry. 1999 Jun;14(6):481-93.
citation: Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, Merchant C, Lantigua R, Costa R, Stern Y, Mayeux R. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001 Jan 9;56(1):49-56. doi: 10.1212/wnl.56.1.49.
citation: Grubs RE, Parker LS, Hamilton R. Subtle psychosocial sequelae of genetic test results. Current Genetic Medicine Reports 2014;2:242-249.